2002 Media releases

11/15/02	Novartis Pharmaceuticals Canada Inc. Invests $15 Million in New National Head Office Building in Montreal
10/09/02	Health Canada Approves Drug that Addresses Unmet Need for Prostate Cancer Patients
09/24/02	Abrupt Discontinuation of Antispasmodic Drug Can Lead to Adverse Events Including Death
08/21/02	McGill University Health Centre Receives $1,000,000 From Novartis Pharmaceuticals Canada Inc.
06/11/02	Novartis Pharmaceuticals Canada Inc. and Oryx Pharmaceuticals Introduce A New Treatment For Epilepsy
05/24/02	New Head-to-Head Data Show Gleevec® (imatinib mesylate) Achieves Nearly Three Times More Responses as First-Line Treatment for Chronic Myeloid Leukemia (CML) Patients than Interferon Combination Therapy
05/19/02	First Head-to-Head Worldwide Study of Leading Breast Cancer Drugs Shows…
01/15/02	World's Smallest Estrogen Replacement Therapy (ERT) Patch Available in Canada